Answer Summary

Members shared their experiences with Brukinsa, a BTK inhibitor prescribed for various forms of non-Hodgkin lymphoma including CLL, MCL, and... Read more

Members shared their experiences with Brukinsa, a BTK inhibitor prescribed for various forms of non-Hodgkin lymphoma including CLL, MCL, and Waldenström macroglobulinemia, with most reporting manageable side effects over extended treatment periods. Several members described mixed results, including one whose husband has been on it over a year with ongoing lymphoma symptoms like chest pain and confusion (possibly medication-related), another who experienced a calcium spike after ten months requiring a three-month break, and one who felt very good after restarting treatment. A recurring theme was the reality that these medications slow progression rather than cure the disease, the importance of reporting new symptoms like shortness of breath or excessive thirst to oncologists, and the trade-off between longer-term oral therapy versus shorter but harsher IV chemotherapy.